JETEMA
LIVE

Serial Number

79260875

Owner

JETEMA CO., LTD.

Attorney

Kisuk Lee

Filing Date

May 3, 2019

Add to watchlist:

No watchlists yet
View on USPTO

JETEMA Trademark

Serial Number: 79260875 • Registration: 6071731

JETEMA is a trademark filed by JETEMA CO., LTD. on May 3, 2019. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

JETEMA CO., LTD. (16 trademarks)

15TH FLOOR, 623, TEHERAN-RO, GANGNAM-GU
SEOUL 06173 , KR

Entity Type: 99

Trademark Details

Filing Date

May 3, 2019

Registration Date

June 9, 2020

Published for Opposition

March 24, 2020

Goods & Services

pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for urogenital organs; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; ophthalmic preparations; allergy medications; pharmaceutical agents for epidermis; pharmaceutical preparations acting on the central nervous system; analgesics; pharmaceutical preparations for respiratory organs; medicines for dental purposes; Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

TEAS SECTION 71 RECEIVED
May 11, 2026 ES71
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 9, 2025 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 17, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 29, 2020 FICS
FINAL DISPOSITION PROCESSED
Sep 29, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 9, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 9, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 24, 2020 NPUB
PUBLISHED FOR OPPOSITION
Mar 24, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 4, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 19, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 30, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 29, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 29, 2020 TROA
TEAS VOLUNTARY AMENDMENT RECEIVED
Jan 29, 2020 PARI
REFUSAL PROCESSED BY IB
Aug 23, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 2, 2019 RFCS
REFUSAL PROCESSED BY MPU
Aug 1, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 16, 2019 RFCR
NON-FINAL ACTION WRITTEN
Jul 15, 2019 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Jul 15, 2019 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 12, 2019 RFCR
NON-FINAL ACTION WRITTEN
Jul 11, 2019 CNRT
ASSIGNED TO EXAMINER
Jul 11, 2019 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 25, 2019 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 20, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 13, 2019 REPR